Andriy Derkach

List of Publications by Year
in descending order

75 papers	1,951 citations	257450 24 h-index	276875 41 g-index
78 all docs	78 docs citations	78 times ranked	4189 citing authors

#	Article	IF	Citations
1	Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis. British Journal of Haematology, 2022, 196, 105-109.	2.5	30
2	Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls. Haematologica, 2022, 107, 284-286.	3.5	4
3	Multicenter evaluation of efficacy and toxicity of venetoclaxâ€based combinations in patients with accelerated and blast phase myeloproliferative neoplasms. American Journal of Hematology, 2022, 97, .	4.1	13
4	Outcomes of Patients with COVID-19 from a Specialized Cancer Care Emergency Room. Cancer Investigation, 2022, 40, 17-25.	1.3	2
5	Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia. Blood Advances, 2022, 6, 3433-3439.	5.2	5
6	BMP2/SMAD pathway activation in JAK2/p53-mutant megakaryocyte/erythroid progenitors promotes leukemic transformation. Blood, 2022, 139, 3630-3646.	1.4	9
7	Nutrition perceptions, needs and practices among patients with plasma cell disorders. Blood Cancer Journal, 2022, 12, 70.	6.2	7
8	Immuneâ€related conditions and cancerâ€specific mortality among older adults with cancer in the United States. International Journal of Cancer, 2022, 151, 1216-1227.	5.1	4
9	Evaluating serum-free light chain ratio as a biomarker for multiple myeloma.. Journal of Clinical Oncology, 2022, 40, 8047-8047.	1.6	1
10	African American patients with smoldering multiple myeloma may have a lower risk of progression compared to White patients.. Journal of Clinical Oncology, 2022, 40, 8045-8045.	1.6	4
11	Clinical efficacy of daratumumab (DARA)-based second line therapy after DARA-containing and DARA-free induction therapies in multiple myeloma: A single center experience.. Journal of Clinical Oncology, 2022, 40, e20005-e20005.	1.6	0
12	Breast Cancer Risk in Women from Ghana Carrying Rare Germline Pathogenic Mutations. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1593-1601.	2.5	3
13	Patterns of Human Leukocyte Antigen Class I and Class II Associations and Cancer. Cancer Research, 2021, 81, 1148-1152.	0.9	15
14	Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia. Blood, 2021, 137, 1377-1391.	1.4	51
15	Initial Whole-Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001. Clinical Cancer Research, 2021, 27, 2111-2118.	7.0	5
16	Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. Nature Communications, 2021, 12, 1861.	12.8	68
17	Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twiceâ€weekly carfilzomib (45 and 56â€‰mg/m²) in combination with lenalidomide and dexamethasone. American Journal of Hematology, 2021, 96, E193-E196.	4.1	10
18	Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood Advances, 2021, 5, 1552-1564.	5.2	102

#	Article	IF	Citations
19	Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms. Clinical Cancer Research, 2021, 27, 3456-3468.	7.0	12
20	Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet Haematology,the, 2021, 8, e422-e432.	4.6	50
21	Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality. Leukemia and Lymphoma, 2021, 62, 1940-1948.	1.3	7
22	Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma. JAMA Oncology, 2021, 7, 862.	7.1	63
23	Arsenic trioxide therapy predisposes to herpes zoster reactivation despite minimally myelosuppressive therapy. Leukemia Research, 2021, 106, 106569.	0.8	2
24	Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma. Nature Communications, 2021, 12, 5172.	12.8	27
25	Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. Leukemia and Lymphoma, 2021, 62, 3394-3401.	1.3	17
26	Clonal hematopoiesis is associated with risk of severe Covid-19. Nature Communications, 2021, 12, 5975.	12.8	81
27	Serum antibody response in patients with philadelphia-chromosome positive or negative myeloproliferative neoplasms following vaccination with SARS-CoV-2 spike protein messenger RNA (mRNA) vaccines. Leukemia, 2021, 35, 3578-3580.	7.2	6
28	P-152: Providing nutritional guidance for patients with plasma cell disorders â€“ a missed opportunity for hematologists and oncologists?. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S118-S119.	0.4	0
29	A Pilot Plant-Based Dietary Intervention in Overweight and Obese Patients with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma- the Nutrition Prevention (NUTRIVENTION) Study. Blood, 2021, 138, 4759-4759.	1.4	1
30	The Genomic Landscape of WaldenstrÃ¶m Macroglobulinemia Reveals Sustained Germinal Center Activity and Late-Developing Copy Number Aberrations. Blood, 2021, 138, 2394-2394.	1.4	0
31	Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience. Blood, 2021, 138, 1644-1644.	1.4	7
32	Clinical and Genomic Characterization of Secondary Acute Myeloid Leukemia with Mixed Phenotype. Blood, 2021, 138, 687-687.	1.4	0
33	P-042: Sustained minimal residual disease negativity in Multiple Myeloma is impacted positively by stool butyrate and healthier plant forward diets. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S61.	0.4	2
34	Prospective Investigation of Serum Metabolites, Coffee Drinking, Liver Cancer Incidence, and Liver Disease Mortality. Journal of the National Cancer Institute, 2020, 112, 286-294.	6.3	53
35	COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers. Blood Cancer Discovery, 2020, 1, 234-243.	5.0	46
36	Chemotherapy and COVID-19 Outcomes in Patients With Cancer. Journal of Clinical Oncology, 2020, 38, 3538-3546.	1.6	195

#	Article	IF	Citations
37	Polygenic risk score for the prediction of breast cancer is related to lesser terminal duct lobular unit involution of the breast. Npj Breast Cancer, 2020, 6, 41.	5.2	5
38	Association of Body Mass Index with Fecal Microbial Diversity and Metabolites in the Northern Finland Birth Cohort. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2289-2299.	2.5	20
39	Group testing in mediation analysis. Statistics in Medicine, 2020, 39, 2423-2436.	1.6	6
40	Hypofibrinogenemia and disseminated intravascular coagulation rarely complicate treatment-naÃ¨ve acute lymphoblastic leukemia. Leukemia and Lymphoma, 2020, 61, 2497-2501.	1.3	1
41	Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. Blood Advances, 2020, 4, 2866-2870.	5.2	81
42	Associations between metabolites and pancreatic cancer risk in a large prospective epidemiological study. Gut, 2020, 69, 2008-2015.	12.1	33
43	Whole-Genome Sequencing Reveals Evidence of Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Myeloma Precursor Disease. Blood, 2020, 136, 47-48.	1.4	2
44	Molecular Predictors and Effectiveness of Measurable Residual Disease (MRD) Eradication with Chemotherapy and Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia. Blood, 2020, 136, 18-20.	1.4	3
45	Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study. Blood, 2020, 136, 18-19.	1.4	0
46	Diabetes Mellitus and Risk of Plasma Cell and Lymphoproliferative Disorders: A Population Based Study Including 94,579 Cases and 368,348 Matched Controls. Blood, 2020, 136, 44-45.	1.4	0
47	Clinical Outcomes of Acute Myeloid Leukemia Patients Bridged to Allogeneic Stem Cell Transplant By Venetoclax Combination Therapy. Blood, 2020, 136, 16-17.	1.4	0
48	Venetoclax Therapy for Relapsed and Treatment Refractory AML: Clinical Outcomes and Molecular Predictors. Blood, 2020, 136, 47-48.	1.4	1
49	VRd Versus KRd Safety Profiles in Newly Diagnosed Multiple Myeloma Patients Using Real-World Evidence Data from a Single Institution: VRd Has High Rates of Chronic Neuropathy, and KRd Has Low Rates of Cardiopulmonary or Renal Toxicities When Using Optimized IV Fluid Management Coupled with Baseline Cardiac Workup. Blood, 2020, 136, 37-38.	1.4	1
50	Impact of Additional Cytogenetic Abnormalities and Complex Karyotype on Event-Free Survival in Acute Promyelocytic Leukemia: Analysis from a Single Academic Center Plus the APML4 Study. Blood, 2020, 136, 34-35.	1.4	0
51	Initial Whole Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001. Blood, 2020, 136, 50-51.	1.4	0
52	Copy Number Signatures Predict Chromothripsis and Poor Clinical Outcome in Newly Diagnosed Multiple Myeloma Patients. Blood, 2020, 136, 52-53.	1.4	2
53	Association of Patient Activity Bioprofiles with Hrqol and Clinical Responses: A Prospective Novel Trial Using Mobile Wearables in Newly Diagnosed Multiple Myeloma Patients. Blood, 2020, 136, 26-28.	1.4	2
54	The association of sleep with metabolic pathways and metabolites: evidence from the Dietary Approaches to Stop Hypertension (DASH)â€"sodium feeding study. Metabolomics, 2019, 15, 48.	3.0	15

#	Article	IF	Citations
55	High Dimensional Mediation Analysis With Latent Variables. Biometrics, 2019, 75, 745-756.	1.4	25
56	Subset testing and analysis of multiple phenotypes. Genetic Epidemiology, 2019, 43, 492-505.	1.3	2
57	The Consortium of Metabolomics Studies (COMETS): Metabolomics in 47 Prospective Cohort Studies. American Journal of Epidemiology, 2019, 188, 991-1012.	3.4	81
58	Prospective serum metabolomic profiling of lethal prostate cancer. International Journal of Cancer, 2019, 145, 3231-3243.	5.1	43
59	Pre-diagnostic Serum Metabolomic Profiling of Prostate Cancer Survival. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 853-859.	3.6	21
60	Associations between IgG reactivity to Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) antigens and Burkitt lymphoma in Ghana and Uganda case-control studies. EBioMedicine, 2019, 39, 358-368.	6.1	20
61	Power Analysis for Genetic Association Test (PAGEANT) provides insights to challenges for rare variant association studies. Bioinformatics, 2018, 34, 1506-1513.	4.1	18
62	Serum Metabolomic Profiling of All-Cause Mortality: A Prospective Analysis in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study Cohort. American Journal of Epidemiology, 2018, 187, 1721-1732.	3.4	29
63	A Comprehensive Analysis of Nuclear-Encoded Mitochondrial Genes in Schizophrenia. Biological Psychiatry, 2018, 83, 780-789.	1.3	35
64	Habitual sleep and human plasma metabolomics. Metabolomics, 2017, 13, 1.	3.0	36
65	Identifying biomarkers of dietary patterns by using metabolomics. American Journal of Clinical Nutrition, 2017, 105, 450-465.	4.7	168
66	Metabolomic Profiling of Serum Retinol in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study. Scientific Reports, 2017, 7, 10601.	3.3	7
67	Effects of dietary sodium on metabolites: the Dietary Approaches to Stop Hypertension (DASH)â€“Sodium Feeding Study. American Journal of Clinical Nutrition, 2017, 106, 1131-1141.	4.7	55
68	Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. British Journal of Cancer, 2016, 115, 1087-1095.	6.4	52
69	Cigarette smoking behaviour and blood metabolomics. International Journal of Epidemiology, 2016, 45, 1421-1432.	1.9	63
70	Score tests for association under response-dependent sampling designs for expensive covariates. Biometrika, 2015, 102, 988-994.	2.4	13
71	A Hypothesis-Driven Association Study of 28 Nuclear-Encoded Mitochondrial Genes with Antipsychotic-Induced Weight Gain in Schizophrenia. Neuropsychopharmacology, 2014, 39, 1347-1354.	5.4	26
72	Evaluation of gene-based association tests for analyzing rare variants using Genetic Analysis Workshop 18 data. BMC Proceedings, 2014, 8, S9.	1.6	7

#	Article	IF	Citations
73	Genetic Analysis Workshop 18 single-nucleotide variant prioritization based on protein impact, sequence conservation, and gene annotation. BMC Proceedings, 2014, 8, S11.	1.6	10
74	Pooled Association Tests for Rare Genetic Variants: A Review and Some New Results. Statistical Science, 2014, 29, .	2.8	60
75	Robust and Powerful Tests for Rare Variants Using Fisher's Method to Combine Evidence of Association From Two or More Complementary Tests. Genetic Epidemiology, 2013, 37, 110-121.	1.3	83